Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aprepitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 18/20 | 0.78 |
| ▸ | TACR3 | P29371 | 2/20 | 0.78 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | FPR1 | P21462 | 1/20 | 0.78 |
| ▸ | GPR183 | P32249 | 1/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.78 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.78 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.78 |
| ▸ | TACR2 | P21452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aprepitant SCHEMBL264924 | 1.00 | TACR1 (0.78) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL16770383 | 1.00 | TACR1 (0.78) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL2687974 | 1.00 | TACR1 (0.78) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL1762934 | 1.00 | TACR1 (0.78) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL1472775 | 1.00 | TACR1 (0.78) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Aprepitant SCHEMBL24067953 | 1.00 | TACR1 (0.78) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL17131462 | 0.97 | TACR1 (0.74) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL16768624 | 0.95 | TACR1 (0.72) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL5223102 | 0.89 | TACR1 (0.62) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL5223100 | 0.89 | TACR1 (0.62) | TACR1TACR3NR3C1CYP3A4FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18791 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137620-A1 | PHARMACEUTICAL EMULSION PROCESS | FRESENIUS KABI USA, LLC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12611410-B2 | Emulsion, injection agent, and emulsion preparation method | KEWPIE CORPORATION (JP) | 2026-04-28 | — | — | US | claimed |
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | KEYZELL HOLDING S L (ES) | 2026-04-16 | — | — | US | claimed |
| US-20260097042-A1 | COMPOUND EMULSION, PREPARATION METHOD THEREFOR, AND USE THEREOF | QILU PHARMACEUTICAL CO LTD (CN) | 2026-04-09 | — | — | US | claimed |
| WO-2005053796-A1 | USE OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS | B & B BEHEER NV (BE) | 2005-06-16 | — | — | WO | claimed |
| EP-1541197-A1 | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists | B&B Beheer NV (BE) | 2005-06-15 | — | — | EP | claimed |
| WO-2005048942-A2 | COMBINATION THERAPY COMPRISING A COX-2 INHIBITOR AND AN ANTINEOPLASTIC AGENT | PHARMACIA CORPORATION (US) | 2005-06-02 | — | — | WO | claimed |
| WO-2005048979-A2 | PHARMACEUTICAL COMPOSITION HAVING CASING WITH MULTIPLE MICRO TABLETS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2005-06-02 | — | — | WO | claimed |
| WO-2005013894-A2 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-02-17 | — | — | WO | claimed |
| WO-2005000807-A2 | BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2005-01-06 | — | — | WO | claimed |
| WO-2004098579-A2 | COMBINATION OF A GLYCINE/NMDA ANTAGONIST AND A TACHYKININ NK-1 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF NEURODEGENERATION | MERCK SHARP & DOHME LIMITED (GB) | 2004-11-18 | — | — | WO | claimed |
| US-20040043071-A1 | Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs | UMD, INC. | 2004-03-04 | — | — | US | claimed |
| US-20040013621-A1 | Transdermal delivery of antiemetics | MONASH UNIVERSITY | 2004-01-22 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |